Skip to main content

Table 4 Prospective associations of plasma tran-fatty acids with risk of cancer mortality (n = 1456)

From: Plasma trans-fatty acids levels and mortality: a cohort study based on 1999–2000 National Health and Nutrition Examination Survey (NHANES)

  Events (n/%) Number at risk (Person-years) Model 1 Model 2 Model 3
  Hazard ratio
(95% CI)
P value Hazard ratio
(95% CI)
P value Hazard ratio
(95% CI)
P value
Elaidic acid (C18:1 t9), μM
Per 10 units increase 60(4.1) 1456 (16034) 1.08(0.98–1.19) 0.137 1.05(0.91–1.23) 0.492 0.88(0.59–1.32) 0.549
Per sd increase 1.18(0.95–1.48) 0.137 1.13(0.80–1.58) 0.492 0.76(0.31–1.86) 0.549
Quartile (Range, μM)
 Quartile 1 (4.5–23.4) 14(3.9) 363(3974) 1.18(0.56–2.52) 0.662 1.42(0.64–3.17) 0.388 1.49(0.66–3.36) 0.336
 Quartile 2 (23.5–32.3) 13(3.6) 363(4078) Reference   Reference   Reference  
 Quartile 3 (32.4–44.7) 13(3.6) 366(4048) 1.29(0.60–2.81) 0.514 1.47(0.67–3.24) 0.340 1.42(0.63–3.18) 0.398
 Quartile 4 (44.9–238) 20(5.5) 364(3934) 1.86(0.92–3.75) 0.085 1.87(0.82–4.26) 0.139 1.65(0.59–4.63) 0.343
Vaccenic acid (C18:1 t11), μM
Per 10 units increase 60(4.1) 1456 (16034) 1.07(0.99–1.16) 0.093 1.07(0.94–1.21) 0.326 1.09(0.82–1.46) 0.553
Per sd increase 1.18(0.97–1.44) 0.093 1.17(0.85–1.61) 0.326 1.25(0.60–2.59) 0.553
Quartile (Range, μM)
 Quartile 1 (4.45–27.9) 12(3.3) 364(3997) 0.86(0.39–1.89) 0.708 0.83(0.36–1.91) 0.655 0.82(0.35–1.92) 0.650
 Quartile 2 (27.9–37.5) 13(3.6) 363(4019) Reference   Reference   Reference  
 Quartile 3 (37.6–49.7) 15(4.1) 364(4036) 1.18(0.56–2.48) 0.667 1.41(0.66–3.03) 0.374 1.46(0.66–3.25) 0.351
 Quartile 4 (49.8–313) 20(5.5) 365(3982) 1.65(0.82–3.31) 0.162 1.73(0.77–3.88) 0.184 2.03(0.68–6.03) 0.205
Palmitelaidic acid (C16:1 t9), μM
Per unit increase 60(4.1) 1456 (16034) 1.05(1.00–1.12) 0.064 1.06(0.97–1.15) 0.176 1.06(0.95–1.18) 0.314
Per sd increase 1.23(0.99–1.52) 0.064 1.25(0.91–1.71) 0.176 1.24(0.81–1.90) 0.314
Quartile (Range, μM)
 Quartile 1 (1.1–5.1) 13(3.6) 363(3989) 1.34(0.61–2.96) 0.467 1.55(0.67–3.57) 0.302 1.56(0.68–3.61) 0.295
 Quartile 2 (5.1–6.8) 12(3.3) 365(4060) Reference   Reference   Reference  
 Quartile 3 (6.9–9.4) 13(3.6) 364(4057) 1.00(0.46–2.20) 0.991 1.30(0.57–2.98) 0.532 1.34(0.57–3.11) 0.500
 Quartile 4 (9.4–33.1) 22(6.0) 364(3928) 1.97(0.97–3.98) 0.059 2.56(1.09–6.00) 0.031 2.91(1.09–7.81) 0.034
Linolelaidic acid (C18:2 t9, 12), μM
Per unit increase 60(4.1) 1456 (16034) 1.12(0.97–1.30) 0.128 1.07(0.85–1.35) 0.562 1.05(0.75–1.47) 0.762
Per sd increase 1.20(0.95–1.51) 0.128 1.11(0.77–1.61) 0.562 1.09(0.63–1.86) 0.762
Quartile (Range, μM)
 Quartile 1 (0.7–2.0) 14(3.8) 364(3975) 1.16(0.55–2.44) 0.694 1.50(0.68–3.28) 0.311 1.58(0.71–3.53) 0.263
 Quartile 2 (2.0–2.7) 14(3.9) 363(4004) Reference   Reference   Reference  
 Quartile 3 (2.7–3.7) 16(4.4) 365(4057) 1.85(0.89–3.83) 0.098 2.00(0.93–4.30) 0.077 1.97(0.90–4.33) 0.089
 Quartile 4 (3.7–13.4) 16(4.4) 364(3998) 1.61(0.78–3.33) 0.199 1.33(0.57–3.12) 0.514 1.24(0.46–3.34) 0.672
  1. Model 1: adjusted for age, gender at baseline
  2. Model 2: further adjusted for race, body mass index, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, triglyceride, total cholesterol, high density lipoprotein, uric acid, estimation glomerular filtration rate, alcohol use, smoking, and self-reported cardiovascular diseases history at baseline
  3. Model 3: further adjusted for other trans-fatty acid subtypes